Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Diclotrex II** is a topical co-packaged analgesic kit marketed by PureTek. It contains diclofenac sodium topical solution 1.5% w/w plus a camphor 4% and menthol 10% topical gel product. Diclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and reduces prostaglandin-mediated pain and inflammation; camphor and menthol provide topical counterirritant analgesia. The diclofenac component is labeled for treatment of the signs and symptoms of osteoarthritis of the knee. The DailyMed listing identifies the product as an unapproved drug other and states that its labeling has not been approved by FDA. ([drugs.com](https://www.drugs.com/pro/diclotrex.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diclotrex II.